133 related articles for article (PubMed ID: 2905254)
1. Interaction of roxatidine acetate with antacids, food and other drugs.
Labs RA
Drugs; 1988; 35 Suppl 3():82-9. PubMed ID: 2905254
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic characteristics of roxatidine.
Bender W; Brockmeier D
J Clin Gastroenterol; 1989; 11 Suppl 1():S6-19. PubMed ID: 2572622
[TBL] [Abstract][Full Text] [Related]
3. The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates.
Tanaka E; Nakamura K
Br J Clin Pharmacol; 1989 Aug; 28(2):171-4. PubMed ID: 2570603
[TBL] [Abstract][Full Text] [Related]
4. Drug interactions between theophylline and H2-antagonists, roxatidine acetate hydrochloride and cimetidine: pharmacokinetic analysis in rats in vivo.
Nagai N; Furuhata M; Ogata H
Biol Pharm Bull; 1995 Nov; 18(11):1610-3. PubMed ID: 8593491
[TBL] [Abstract][Full Text] [Related]
5. [Effects of the histamine H2 receptor antagonist roxatidine acetate on stomach and liver alcohol dehydrogenase and serum alcohol level].
Beil W; Sewing KF
Z Gastroenterol; 1993 Nov; 31(11):643-5. PubMed ID: 7904786
[TBL] [Abstract][Full Text] [Related]
6. A review of the animal pharmacology of roxatidine acetate.
Scholtholt J; Bickel M; Herling AW
Drugs; 1988; 35 Suppl 3():30-40. PubMed ID: 2905247
[TBL] [Abstract][Full Text] [Related]
7. Chemical and biologic characteristics of roxatidine acetate.
Bickel M; Herling AW; Schoelkens B; Scholtholt J
Scand J Gastroenterol Suppl; 1988; 146():78-88. PubMed ID: 2906471
[TBL] [Abstract][Full Text] [Related]
8. The effects of roxatidine acetate on 24-hour intragastric acidity. Investigations in healthy volunteers and comparison with ranitidine and placebo.
Merki HS; Witzel L; Kaufmann D; Kempf M; Neumann J; Scheurle E; Röhmel J; Walt RP
Drugs; 1988; 35 Suppl 3():69-75. PubMed ID: 2905252
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacology of histamine H2-receptor antagonists.
Sewing KF; Beil W; Hannemann H
Drugs; 1988; 35 Suppl 3():25-9. PubMed ID: 2905246
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of roxatidine in healthy volunteers.
Collins JD; Pidgen AW
Drugs; 1988; 35 Suppl 3():41-7. PubMed ID: 2905248
[TBL] [Abstract][Full Text] [Related]
11. The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.
Lassman HB; Ho I; Puri SK; Sabo R; Scheffler MR
Drugs; 1988; 35 Suppl 3():53-64. PubMed ID: 2905250
[TBL] [Abstract][Full Text] [Related]
12. Effect of roxatidine acetate on daytime and night-time peptone-stimulated gastric acid secretion.
Hagenmüller F
Drugs; 1988; 35 Suppl 3():65-8. PubMed ID: 2905251
[TBL] [Abstract][Full Text] [Related]
13. Effects of roxatidine acetate on 24-hour gastric acidity. Early evening versus bedtime administration in healthy subjects.
Hemery P; Congard P; Galmiche JP; Bonfils S
Drugs; 1988; 35 Suppl 3():76-81. PubMed ID: 2905253
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea.
Sekiguchi H; Hamada K; Kobayashi F; Taga F; Uchida H
Arzneimittelforschung; 1993 Feb; 43(2):129-33. PubMed ID: 8096132
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic approach in patients with concomitant disease/drug--drug interactions (roxatidine acetate).
Collins JD
Scand J Gastroenterol Suppl; 1988; 146():89-99. PubMed ID: 2906472
[TBL] [Abstract][Full Text] [Related]
16. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders.
Murdoch D; McTavish D
Drugs; 1991 Aug; 42(2):240-60. PubMed ID: 1717223
[TBL] [Abstract][Full Text] [Related]
17. Comparison of roxatidine acetate and ranitidine in the treatment of reflux esophagitis. The Roxatidine Esophagitis Study Group.
Clin Ther; 1993; 15(2):283-93. PubMed ID: 8100189
[TBL] [Abstract][Full Text] [Related]
18. Cytoprotective action of roxatidine acetate HCl.
Shiratsuchi K; Fuse H; Hagiwara M; Mikami T; Miyasaka K; Sakuma H
Arch Int Pharmacodyn Ther; 1988; 294():295-304. PubMed ID: 2906796
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Stass H; Böttcher MF; Ochmann K
Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
